|
Market Closed -
Nasdaq
16:00:00 2026-08-31 EDT
|
5-day change | 1st Jan Change | ||
| 123.22 USD | -0.92% |
|
-3.72% | +24.75% |
| 08-28 | US FDA approves Takeda, Protagonist's drug for rare blood cancer | RE |
| 08-28 | Incyte Partner Knight Seeks Supplemental Approval for Minjuvi Combination in Brazil | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Biopharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 25.21B | |||||
| 79.3B | |||||
| 59.21B | |||||
| 55.09B | - | ||||
| 49.86B | |||||
| 47.9B |
- Stock Market
- Stocks
- INCY Stock
- Charts Incyte Corporation
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
